Clinical Trials Browser

Phase 2 × mirdametinib × Clear all

NCT07061951 2026-04-13

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07521657 2026-04-13

NF118

Phase 2 Not yet recruiting

Glioblastoma, Glioma, Neurofibromatosis 1

NCT03962543 2026-04-08

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 3 FDA

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT05983159 2026-02-19

TARGET-VM

Phase 2 Recruiting

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Phase 2 Recruiting

CNSDermatologic

Melanoma, Neurofibromatoses

NCT02096471 2019-01-10

MEK Inhibitor

Phase 2 Completed

19 enrolled 14 charts

Neurofibroma, Neurofibromatosis 1

NCT00174369 2009-03-17

MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung